Kymera Therapeutics has filed a patent for compounds, compositions, and methods of using them. The abstract does not provide specific details, and the claim has been canceled. GlobalData’s report on Kymera Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Kymera Therapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Kymera Therapeutics's grant share as of September 2023 was 8%. Grant share is based on the ratio of number of grants to total number of patents.
The filed patent (Publication Number: US20230303526A1) describes a compound of formula I'-b. The compound has various features and characteristics as outlined in the claims.
Claims 28 and 29 specify the structure of the compound, stating that Ring P is a 5-membered heteroaryl ring with 1-4 heteroatoms chosen from nitrogen, oxygen, and sulfur, while Ring Q is a 6-membered heteroaryl ring with 1-4 nitrogen atoms.
Claim 30 introduces Ring T, which is a 9-membered bicyclic heteroaryl ring with 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
Claim 31 mentions that the R group attached to Ring P has x equal to 0.
Claim 32 further specifies the R group attached to Ring Q, stating that x is equal to 1 and Rx is -NR2. In this case, one R of the -NR2 group is hydrogen, and the other R can be an optionally substituted C1-6 aliphatic group, an optionally substituted 4-7 membered saturated or partially unsaturated heterocyclic group with 1-2 heteroatoms chosen from nitrogen, oxygen, and sulfur, or an optionally substituted 5-6 membered heteroaryl ring with 1-4 heteroatoms chosen from nitrogen, oxygen, and sulfur.
Claim 34 mentions that X, which is part of the compound's structure, can be a covalent bond.
Claim 35 expands on the possibilities for X, stating that it can be a 4-6 membered saturated carbocyclic or heterocyclic ring with 1-2 heteroatoms chosen from nitrogen, oxygen, and sulfur.
Claims 37, 38, and 39 describe the options for Ring D, which can be phenyl or a 6-membered heteroaryl ring containing 1-4 nitrogen atoms.
Claims 42 and 43 specify the possibilities for R3a, which can be hydrogen, methyl, -CF3, fluoro, chloro, -CN, or -OMe.
Claims 44 and 45 mention that the value of n can be either 0 or 1.
Finally, claim 46 states that -Cy- is N, and claim 47 introduces the variable L, which is not further specified.
In summary, the filed patent describes a compound with a specific structure and various possible substitutions and variations. The compound includes heteroaryl rings with nitrogen, oxygen, and sulfur atoms, and can have different substituents attached to these rings. The patent also mentions the possibility of a covalent bond or a saturated carbocyclic or heterocyclic ring with heteroatoms as part of the compound's structure. The patent does not provide specific details about the compound's potential applications or uses.
To know more about GlobalData’s detailed insights on Kymera Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
